Evolus Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:EOLS Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
06 Sep 24	SellUS$49,074	Sandra Beaver	Individual	3,276	US$14.98
30 Aug 24	SellUS$89,251	Tomoko Yamagishi-Dressler	Individual	5,631	US$15.85
04 Jun 24	SellUS$1,784,686	David Moatazedi	Individual	140,214	US$12.73
03 Jun 24	SellUS$97,203	Vikram Malik	Individual	7,500	US$12.96
14 May 24	SellUS$131,010	David Gill	Individual	10,361	US$12.72
13 May 24	SellUS$362,012	Vikram Malik	Individual	28,000	US$12.93
10 May 24	SellUS$30,814	Sandra Beaver	Individual	2,423	US$12.72
10 May 24	SellUS$43,761	Rui Avelar	Individual	3,441	US$12.72
10 May 24	SellUS$204,127	David Moatazedi	Individual	16,051	US$12.72
27 Mar 24	SellUS$86,431	David Moatazedi	Individual	6,236	US$13.86
19 Mar 24	SellUS$1,344,604	David Moatazedi	Individual	96,566	US$13.92
19 Mar 24	SellUS$78,978	Sandra Beaver	Individual	5,672	US$13.92
19 Mar 24	SellUS$384,350	Rui Avelar	Individual	27,603	US$13.92
22 Feb 24	SellUS$100,804	David Moatazedi	Individual	7,706	US$13.08
08 Dec 23	SellUS$822,396	David Moatazedi	Individual	82,648	US$10.09
16 Oct 23	SellUS$12,679,973	Medytox Korea Co. Ltd	Company	1,690,663	US$7.50

Insider Trading Volume

Insider Buying: EOLS insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of EOLS?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	1,248,032	1.98%
General Public	2,420,722	3.84%
Public Companies	3,136,869	4.97%
Private Companies	3,381,326	5.36%
VC/PE Firms	5,753,798	9.12%
Institutions	47,153,735	74.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.

Top Shareholders

Top 25 shareholders own 77.42% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.12%	Perceptive Advisors LLC	5,753,798	US$91.8m	0%	2.08%
7.68%	Tang Capital Management, LLC	4,847,399	US$77.3m	16.9%	6.96%
6.35%	BlackRock, Inc.	4,008,182	US$63.9m	22.9%	no data
5.36%	Medytox Korea Co. Ltd	3,381,326	US$53.9m	0%	no data
4.97%	Daewoong Pharmaceutical Co., Ltd	3,136,869	US$50.0m	0%	no data
4.73%	The Vanguard Group, Inc.	2,985,215	US$47.6m	2.74%	no data
4.61%	Nantahala Capital Management, LLC	2,910,849	US$46.4m	0%	4.15%
3.89%	Great Point Partners, LLC	2,451,772	US$39.1m	0.07%	7.6%
3.44%	Caligan Partners, LP	2,167,790	US$34.6m	14.8%	10.5%
2.63%	Stonepine Capital Management LLC	1,657,611	US$26.4m	-38%	9.46%
2.44%	Deutsche Asset & Wealth Management	1,541,293	US$24.6m	0.07%	0.01%
2.27%	Morgan Stanley, Investment Banking and Brokerage Investments	1,434,122	US$22.9m	-52.5%	no data
2.12%	State Street Global Advisors, Inc.	1,339,077	US$21.4m	29.7%	no data
1.9%	Geode Capital Management, LLC	1,199,594	US$19.1m	25%	no data
1.83%	Soleus Capital Management, L.P.	1,152,000	US$18.4m	620%	1.5%
1.58%	Boothbay Fund Management, LLC	996,510	US$15.9m	2.41%	0.55%
1.55%	Schroder Investment Management North America Inc.	977,629	US$15.6m	17.4%	0.05%
1.5%	Assenagon Asset Management S.A.	947,103	US$15.1m	5,630%	0.03%
1.45%	Medical Strategy GmbH, Asset Management Arm	913,703	US$14.6m	-13.1%	0.84%
1.43%	Millennium Management LLC	899,377	US$14.3m	-3.95%	0.01%
1.38%	D. E. Shaw & Co., L.P.	871,098	US$13.9m	-10.9%	0.02%
1.35%	Rice Hall James & Associates, LLC	851,295	US$13.6m	-3.34%	0.78%
1.35%	Soros Fund Management LLC	850,000	US$13.6m	1.18%	0.38%
1.28%	Lord, Abbett & Co. LLC	806,764	US$12.9m	-2.86%	0.04%
1.22%	UBS Asset Management AG	769,403	US$12.3m	20.6%	no data